After launching its flagship oral insulin spray in Ecuador last
December, Generex is finally gearing up to take on big pharma in
the global non-injectable insulin arena and has picked Cardinal
Health to help meet manufacturing demands.
Continuing its aggressive entry into Europe's custom manufacturing
arena, Nicholas Piramal (NPIL) has today acquired Pfizer's
manufacturing facility in Northumberland, in a deal that could earn
it more than $350m (€280m)...
The boom in advanced drug delivery devices is creating demand for
specialist manufacturers that can rise to the challenge of making
these complicated devices, although such companies are currently
thin on the ground.
Pfizer has sold a large manufacturing plant in Puerto Rico to
biopharmaceutical firm Abraxis for $32.5m (€25.4m), as it continues
to consolidate its manufacturing operations.
AstraZeneca, Baxter BioPharma Solutions, Daiichi Asubio Pharma,
Janssen Pharmaceutica and Wyeth Pharmaceuticals are the finalists
competing for this year's Facility of the Year Award, which
recognizes innovation and cost effectiveness...
UK medical technology producers, Bespak reported healthy sales and
profit figures the first half period, identifying three areas of
prosperity, which could spell future growth within established
markets and opportunities worldwide.
Bruker Optics have reached an agreement with the Chinese State Food
and Drug Administration (SFDA), which sees Bruker technology
integrated into regional Food and Drug Administration offices
aiding the fight against illegal counterfeit...
Chromos has announced an expansion to an existing Pfizer
collaboration, which builds on research focusing on genetic
engineering of production cell lines with multiple genes to improve
bioreactor performance and reduce monoclonal...
The firing of Dr Peter Rost by Pfizer highlights the position that
employees can be faced with if they take a stand on what they
believe to be illegal activity in the companies they work for.
The interest in Syntonix' SynFusion and Transceptor technologies
intensified as Boehringer Ingelheim became the second
pharmaceutical company to use this technology to optimise its
therapeutic peptides for inhalation.
Codexis has achieved a second technical milestone, earlier than
expected, in a collaboration with Pfizer aimed at developing new
biocatalysts for the manufacture of the number one drugmaker's
products.
Vioxx. Bextra. Zyprexa, Seroxat. At no period of time have so many
high-profile drugs come under the spotlight as drug companies face
legal action over drug safety. It's make or break time for the
pharmaceutical industry as drug...
Nektar Therapeutics is planning to buy fellow drug delivery
specialist Aerogen for $32 million (€26m), boosting its position in
respiratory technologies.
Pfizer has started production at a newly opened $90m plant
expansion in Ireland that will make torcetrapib, a cardiovascular
drug in late-stage clinical testing, reports Phil Taylor.
Pfizer has struck a deal to buy Vicuron Pharmaceuticals, for $1.9
billion (€1.6 billion) in cash, in a move that places the drug
company further into the realms of anti-infective R&D - an area
thought to be falling out of favour...
The discovery of a new batch of counterfeit drugs circulating in
the US market adds urgency to ongoing efforts to improve
traceability in the medicines supply chain, and will also lend
weight to arguments against parallel trade in...
The world's largest drug firm, Pfizer, warned that 2005 would be
its "toughest year ever" as the pharmaceutical company detailed
restructuring plans to save $4 billion (€3.1 billion) in costs
every year as well as cushion...
The world's number one drug company, Pfizer, yesterday announced
cost-cutting measures aimed at saving $4 billion (€3.1bn) by 2008,
as it faces a raft of patent expirations on its top drugs and
continued pressure on its painkiller...
The world's number one pharmaceutical company, Pfizer, is to close
a plant in Michigan, US, as part of a drive to reduce its global
manufacturing capacity.
The world's largest drug company, Pfizer, is to make use of a gene
expression system developed at Dowpharma for the production of one
of its therapeutic proteins.
Pfizer is to acquire Idun Pharmaceuticals in an agreement, which
includes a new technology platform with potential applications in
liver disease, inflammation and cancer.
The Generic Pharmaceutical Association (GPhA) has praised the Food
and Drug Administration for validating the science of generic
biopharmaceuticals and making significant progress in establishing
requirements to approve these medicines.
An emerging trend has identified an emergence of combination drugs,
which could be a solution to patient non-compliance, a major factor
in the rise of drug resistant microorganisms in the industrialised
nations.
The safety of cox-2 inhibitors was plunged into further uncertainty
after Pfizer released details of trials that found an increased
risk of heart problems with patients taking its painkiller
Celebrex. The drug is in the same class...
Drug giant Pfizer is planning to buy UK-based drug delivery company
Meridica in a move that it says will bolster its activities in
allergy and respiratory medicine.
Rumours of the demise of Ireland as a hotbed of pharmaceutical
manufacturing may be premature. Pfizer has just unveiled a plan to
spend €240 million to expand its Dun Laoghaire plant in Dublin.
China has defended its decision to overturn Pfizer's patent on its
blockbuster drug for erectile dysfunction, Viagra (sildenafil), in
a ruling that was seen as a blow to hopes that the country would
enforce intellectual property...
The number one drugmaker - Pfizer - has stepped up its legal
campaign against the trade in counterfeit versions of its
top-selling drug Lipitor (atorvastatin), one of the most copied
drugs on the market.
Pfizer's position as the number one drugmaker in the world with a
stable of blockbuster medications makes it a prime target for the
drug counterfeiters, and one of its most copied products is the
notorious impotence drug Viagra...
Dr Reddy's Laboratories of India has lost its bid to market a
generic version of Pfizer's blockbuster hypertension drug Norvasc
(amlodipine besylate) in a development that could spell trouble for
companies hoping to market...
Germany's Altana has filed for European marketing approval of the
first drug in new class - the phosphodiesterase-4 inhibitors - for
asthma and chronic obstructive pulmonary disease.
Earlier this week, the US Food and Drug Administration suspended
the approval of a generic version of Pfizer's high blood pressure
drug Norvasc (amlodipine besylate) developed by India's Dr Reddy's
Laboratories. The...
Drug major Eli Lilly has provided a detailed response to a US
congressional committee request for details of how the firm intends
to tackle the issue of drug counterfeiting.
Healthcare giant Cardinal Health reported revenues up 11 per cent
to $14.1 billion (€11.2bn) in the fourth-quarter of 2003, as a
strong performance in its pharmaceutical manufacturing services,
pharmacy automation and medical product...
A US congressional committee has asked five drug makers for advice
on the measures they are taking to combat the counterfeiting and
diversion of prescription drugs.
Meridica has licensed its newly-designed Xcelovair dry powder
inhaler (DPI) to Pfizer in what amounts to something of a coup for
the small UK start-up.
US pharmaceuticals major Pfizer is considering moving some of its
activities in Germany to the UK due to government health reforms;
meanwhile, Merck & Co has shelved plans to open a new R&D
facility in the country.
A new report from Datamonitor predicts the end of the
pharmaceutical industry's blockbuster product model, pointing to a
dramatic shortfall in growth rates for billion dollar-plus products
out to 2008.
US pharmaceutical major Pfizer reinforced its position as the
world's largest drug company in 2002 after putting in sales of
$29.45 billion (€25.12 bn) in 2002, a hike of 11 per cent over the
prior year, according to a new analysis...
The European Commission has given Pfizer the all clear to acquire
Pharmacia corporation - paving the way for the creation of the
largest pharmaceutical company in the world.
